TELA Bio (TELA) to Release Quarterly Earnings on Thursday

TELA Bio (NASDAQ:TELA) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. TELA Bio has set its FY 2024 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

TELA Bio (NASDAQ:TELA) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The business had revenue of $17.00 million for the quarter, compared to analyst estimates of $16.65 million. TELA Bio had a negative return on equity of 201.62% and a negative net margin of 79.83%. On average, analysts expect TELA Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Stock Up 7.2 %

Shares of TELA opened at $4.92 on Wednesday. The company’s 50-day moving average price is $5.31 and its 200 day moving average price is $5.89. TELA Bio has a 12-month low of $4.23 and a 12-month high of $11.26. The company has a current ratio of 4.23, a quick ratio of 3.45 and a debt-to-equity ratio of 2.15. The firm has a market cap of $121.28 million, a P/E ratio of -2.38 and a beta of 1.00.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on TELA shares. Piper Sandler decreased their price objective on shares of TELA Bio from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, March 22nd. JMP Securities restated a “market outperform” rating and set a $15.00 price target on shares of TELA Bio in a research report on Friday, March 22nd.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.